Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery

被引:33
作者
Burkhardt, O
Majcher-Peszynska, J
Borner, K
Mundkowski, R
Drewelow, B
Derendorf, H
Welte, T
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
[2] Univ Magdeburg, Dept Pulm & Crit Care Med, D-39106 Magdeburg, Germany
[3] Hannover Med Sch, Dept Pulm Med, D-3000 Hannover, Germany
[4] Univ Rostock, Dept Clin Pharmacol, Rostock, Germany
[5] Free Univ Berlin, Dept Clin Chem & Pathobiochem, D-1000 Berlin, Germany
关键词
ertapenem; pharmacokinetics; plasma; lung tissue; ELF; alveolar cells; CAP;
D O I
10.1177/0091270005276117
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ertapenem is approved for the treatment of community-acquired pneumonia ( CAP), but its in vivo penetration into lung tissue ( LT), epithelial lining fluid ( ELF), and alveolar cells ( AC) is unknown. Fifteen patients undergoing thoracotomy were treated with 1 g intravenously for perioperative prophylaxis. Bronchoalveolar lavage was performed 1, 3, and 5 hours after ertapenem infusion. Normal LT was sampled at the time of lung extraction. Blood was collected before and at different time points up to 24 hours after infusion. Mean concentrations of ertapenem in plasma, ELF, and AC were at 1.0 hour, 63.1, 4.06, 0.004 mg/L; at 3.0 hours, 39.7, 2.59, 0.003 mg/L; and at 5.0 hours, 27.2, 2.83, 0.007 mg/L. Mean ( range) concentration in LT was 7.60 ( 2.5 - 19.4) mg/kg tissue 1.5 to 4.5 hours after infusion. In plasma, ertapenem exhibited a C-max of 94.7 +/- 23.3 mg/L and an AUC(0-last) of 501.1 +/- 266.3 mg.h/ L. These results, combined with the reported ( MIC) 90 of most CAP bacteria, support the previously observed clinical efficacy of ertapenem in the treatment of CAP.
引用
收藏
页码:659 / 665
页数:7
相关论文
共 30 条